8 research outputs found
Choroidal structure as a biomarker for visual acuity in intravitreal aflibercept therapy for polypoidal choroidal vasculopathy
<div><p>Purpose</p><p>To investigate the relationship between choroidal structure and visual acuity after intravitreal aflibercept therapy for polypoidal choroidal vasculopathy (PCV).</p><p>Methods</p><p>We conducted a retrospective, single-centre and observational study including 18 eyes of 18 patients with PCV (73.8 ± 10.2 years of age) who were treated with three monthly intravitreal aflibercept injections followed by additional treatments in a treat-and-extend protocol. The cross-sectional images of the macula were obtained with enhanced depth imaging optical coherence tomography at baseline, at 3 months, and at 12 months. The choroidal layer was divided into luminal or stromal segments by applying binarization processing to calculate these areas. The relationships between age, spherical equivalent, best-corrected visual acuity (BCVA), baseline value, or changes in the luminal or the stromal areas, and the BCVA change at 12 months were analysed using multiple regression analyses and model selection procedures.</p><p>Results</p><p>Both stromal and luminal areas were decreased at 3 and 12 months compared to baseline areas (5% and 9% at 3 months, 6% and 12% at 12 months, p < 0.0001, p < 0.0001, p < 0.0001 and p < 0.0001, respectively). Greater improvement of visual acuity (VA) at 12 months was significantly associated with younger age, greater spherical equivalent, worse baseline BCVA, greater baseline luminal area, and smaller baseline stromal area.</p><p>Conclusions</p><p>Choroidal structure might be useful as a new biomarker for potential Visual outcomes after intravitreal aflibercept therapy for PCV.</p></div
Multivariate analyses between ΔBCVA12 and variables using binarization of the choroid at baseline, 3 and 12 months in polypoidal choroidal vasculopathy (PCV) with intravitreal aflibercept injections.
<p>Multivariate analyses between ΔBCVA12 and variables using binarization of the choroid at baseline, 3 and 12 months in polypoidal choroidal vasculopathy (PCV) with intravitreal aflibercept injections.</p
Baseline characteristics and number of injections of the patients.
<p>Baseline characteristics and number of injections of the patients.</p
Univariate analyses between ΔBCVA<sub>12</sub> and variables in polypoidal choroidal vasculopathy (PCV) with intravitreal aflibercept injections.
<p>Univariate analyses between ΔBCVA<sub>12</sub> and variables in polypoidal choroidal vasculopathy (PCV) with intravitreal aflibercept injections.</p
Changes in choroidal area in polypoidal choroidal vasculopathy (PCV) with intravitreal aflibercept injections.
<p>Changes in choroidal area in polypoidal choroidal vasculopathy (PCV) with intravitreal aflibercept injections.</p
Multivariate analyses between ΔBCVA<sub>12</sub> and variables without binarization of choroid at baseline,3 and 12 months in polypoidal choroidal vasculopathy (PCV) with intravitreal aflibercept injections.
<p>Multivariate analyses between ΔBCVA<sub>12</sub> and variables without binarization of choroid at baseline,3 and 12 months in polypoidal choroidal vasculopathy (PCV) with intravitreal aflibercept injections.</p
Segmentation and binarization of EDI-OCT images.
<p>(Top) From the enhanced depth imaging optical coherence tomography images, subfoveal choroidal layers under the Bruch’s membrane were divided into three sectors with each width of 1,000 μm (yellow boxes). (Buttom) The Niblack auto local threshold was applied to binarize the images to subdivide them into the stromal and luminal choroid. Then, areas were calculated using the built-in measurement tool in ImageJ.</p
Additional file 1: of The Japanese version of the questionnaire about the process of recovery: development and validity and reliability testing
Japanese version of the Questionnaire about the Process of Recovery (QPR-J). (PDF 133 kb